Zydus Cadila gets USFDA nod to market anti-bacterial drug to cure respiratory, skin, ear and sexually transmitted disease

AHMEDABAD | MUMBAI | RAJKOT – Zydus Cadila (Cadila Healthcare Ltd) has received the final approval from the USFDA to market Azithromycin for Oral Suspension USP (US RLD – Zithromax), 100 mg/5 mL and 200 mg/5 mL, the company said in the press release submitted to Exchanges in India on Wednesday.

This medication contains Azithromycin, a macrolide antibiotic that fights bacteria.

It is used to treat different types of bacterial infections such as respiratory infections, skin infections, ear infections and sexually transmitted diseases.

This medication will not work for Viral infections such as common cold, flu etc. The drug will be manufactured at the group’s formulations manufacturing facility at Baddi.

In line with this, the group now has 213 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in ‘FY 2003-04.

Announcement somehow seem to have not cheered the investors & traders, as the company shares prices pivoted in negative territories after the announcement hit the exchange and company shares were seen trading in RED Zone on negative counters on Wednesday.